Kardi Ai closed a 5.3 million euro Series A on November 11, led by German healthtech fund Callisto Health at a 23 million euro post-money valuation. Česká spořitelna and Slovenská sporiteľňa joined through their Seed Starter programs, alongside returning backers BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. BrightCap led the 2022 pre-seed.
The company, founded in Olomouc in 2022, sells a fitness chest strap with a built-in ECG sensor, paired with a phone app and model-based analysis of the recordings. It reports more than 6,000 users in the Czech Republic, more than 70 hospitals and more than 20 corporate and benefits partners there, plus more than 20 physicians in Slovakia. Kardi says it flags possible arrhythmias in about a quarter of users, including more than 500 critical findings, and positions the output as decision support rather than diagnosis.
The money goes to Germany first, then India, the UAE and Singapore. Kardi holds MDR certification, an MD-15 import licence from India's CDSCO granted in July 2026 and a device registration certificate from the UAE's MOHAP, with Singapore pending. The predictive arrhythmia-risk models it wants to build still need clinical validation and their own clearance.